480 related articles for article (PubMed ID: 33514401)
1. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
4. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
6. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
7. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
8. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
9. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
[TBL] [Abstract][Full Text] [Related]
10. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
[TBL] [Abstract][Full Text] [Related]
11. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
Front Immunol; 2021; 12():628906. PubMed ID: 33777013
[TBL] [Abstract][Full Text] [Related]
12. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
13. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
15. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
[TBL] [Abstract][Full Text] [Related]
17. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
18. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors.
Theruvath J; Sotillo E; Mount CW; Graef CM; Delaidelli A; Heitzeneder S; Labanieh L; Dhingra S; Leruste A; Majzner RG; Xu P; Mueller S; Yecies DW; Finetti MA; Williamson D; Johann PD; Kool M; Pfister S; Hasselblatt M; Frühwald MC; Delattre O; Surdez D; Bourdeaut F; Puget S; Zaidi S; Mitra SS; Cheshier S; Sorensen PH; Monje M; Mackall CL
Nat Med; 2020 May; 26(5):712-719. PubMed ID: 32341579
[TBL] [Abstract][Full Text] [Related]
19. Development of T-cell engagers selective for cells co-expressing two antigens.
Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
